Company Hosting Educational Program on OFF Periods and Presenting
Data at Upcoming 4th World Parkinson Congress
ARDSLEY, N.Y.–(BUSINESS WIRE)–#OFFperiods–Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced it has launched
a new community resource for people with Parkinson’s, “The
Many Faces of OFFSM1” Facebook page. The site,
which is going live in conjunction with the upcoming 4th
World Parkinson Congress (WPC), will provide a forum for people with
Parkinson’s to learn more about OFF periods and connect with each other
to share experiences.
OFF periods are characterized by the re-emergence of Parkinson’s
symptoms, including motor symptoms such as the impaired ability to move,
muscle stiffness, and tremor.
“People with Parkinson’s regularly tell us that they need more
information about OFF periods and would also value an online forum
dedicated to the impact of OFF, as they don’t always have a dialogue
with their healthcare team about these experiences,” said David
Squillacote, M.D., Vice President, Medical Affairs for Acorda. “We
established this new resource to provide high-quality content from the
community and healthcare professionals, and to enable discussions about
OFF among people with Parkinson’s.”
“The Many Faces of OFF” Facebook page includes videos of people with
Parkinson’s and care partners talking about their personal challenges of
OFF. The page also provides explanations of key concepts and tips for
living with OFF periods, and is expected to host Parkinson’s disease
events. Importantly, the page encourages the Parkinson’s community to
participate and share their stories.
Acorda is launching the Facebook page as part of a broader educational
initiative around OFF periods. At this year’s WPC, being held September
20-23 in Portland, OR, Acorda is hosting a symposium entitled “The Many
Faces of OFF: Realities and Impact.” This symposium will feature people
with Parkinson’s discussing their experience with OFF periods, while
movement disorder specialists Raj Pahwa, M.D. and Larry Elmer, M.D,
Ph.D. will discuss the impact of OFF, and challenges to effective
communication of this impact between people with Parkinson’s and their
“The Many Faces of OFF” symposium is being held on September 22 at 7:00
pm and is open to all WPC attendees. Registration information can be
Acorda will also host an interactive experience about OFF periods at its
“The Many Faces of OFF” booth (WPC Booth #800).
Acorda is also presenting several research posters at WPC.
Approximately one million Americans, 1.2 million Europeans, and between
seven and ten million people worldwide suffer from Parkinson’s disease.
1 The Many Faces of OFF is a service mark of Acorda
About Parkinson’s Disease and OFF Periods
Parkinson’s disease is a progressive neurodegenerative disorder
resulting from the gradual loss of certain neurons responsible for
producing dopamine, which causes impairment of motor function including
impaired ability to move, muscle stiffness and tremors. Non-motor
symptoms are also common; they include anxiety, depression, sleep
difficulties and gastrointestinal (GI) challenges among others.
As Parkinson’s disease progresses, people with Parkinson’s experience
OFF periods, during which symptoms re-emerge. OFF periods increase in
frequency and severity during the course of the disease.
In the United States, approximately 350,000 people with Parkinson’s
experience OFF periods. OFF periods are inadequately addressed by
available therapies and are considered one of the greatest unmet medical
needs facing people with Parkinson’s disease.
About Acorda Therapeutics
Founded in 1995, Acorda
Therapeutics is a biotechnology company focused on developing
therapies that restore function and improve the lives of people with
For more information, please visit the Company’s website at: www.acorda.com.
This press release includes forward-looking statements. All statements,
other than statements of historical facts, regarding management’s
expectations, beliefs, goals, plans or prospects should be considered
forward-looking. These statements are subject to risks and uncertainties
that could cause actual results to differ materially, including: the
ability to complete the Biotie transaction on a timely basis; the
ability to realize the benefits anticipated from the Biotie and Civitas
transactions, among other reasons because acquired development programs
are generally subject to all the risks inherent in the drug development
process and our knowledge of the risks specifically relevant to acquired
programs generally improves over time; the ability to successfully
integrate Biotie’s operations and Civitas’ operations, respectively,
into our operations; we may need to raise additional funds to finance
our expanded operations and may not be able to do so on acceptable
terms; our ability to successfully market and sell
Ampyra (dalfampridine) Extended Release Tablets, 10 mg in the U.S.;
third party payers (including governmental agencies) may not reimburse
for the use of Ampyra or our other products at acceptable rates or at
all and may impose restrictive prior authorization requirements that
limit or block prescriptions; the risk of unfavorable results from
future studies of Ampyra or from our other research and development
programs, including CVT-301 or any other acquired or in-licensed
programs; we may not be able to complete development of, obtain
regulatory approval for, or successfully market CVT-301, any other
products under development, or the products that we will acquire when we
complete the Biotie transaction; the occurrence of adverse safety events
with our products; delays in obtaining or failure to obtain and maintain
regulatory approval of or to successfully market Fampyra outside of the
U.S. and our dependence on our collaborator Biogen in connection
therewith; competition; failure to protect our intellectual property, to
defend against the intellectual property claims of others or to obtain
third party intellectual property licenses needed for the
commercialization of our products; and failure to comply with regulatory
requirements could result in adverse action by regulatory agencies.
These and other risks are described in greater detail in our filings
with the Securities and Exchange Commission. We may not actually achieve
the goals or plans described in our forward-looking statements, and
investors should not place undue reliance on these statements.
Forward-looking statements made in this presentation are made only as of
the date hereof, and we disclaim any intent or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this presentation.
Jeff Macdonald, 914-326-5232